$2.87-1.4%Nov 13 close
Reported results on November 4, 2026; they are not in these figures yet.
Next earnings: November 18, 2026
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
Lexeo Therapeutics, Inc. is scheduled to report next on November 18, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$25.9M | -$26.1M | +0.90% |
| Profit per share | -$0.30 | -$0.60 | +50.00% |
| Free Cash Flow | -$17.6M | -$28.3M | +37.85% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. 2
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lexeo Therapeutics, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Lexeo Therapeutics, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.